A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar and lose weight.

Recruiting now. Registry record last updated August 4, 2026.

Who can join: Adults 18 to 30, have type 1 diabetes, BMI 27+.
What you take: semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 3.9 years; your own time in it is usually shorter.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 2Sponsor Yale UniversityDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 54

What this study is for

Primary condition: Diabetes type1. Also studied in: Obesity.

Full scientific study title: Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment.

Who can join

Age18 to 30SexAnyBMI27 or higher

Adults 18 to 30, have type 1 diabetes, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Age 18-30 years with T1D whose BMI meets FDA approval criteria for anti-obesity pharmacotherapy (BMI ≥30 kg/m2 alone or BMI ≥27 kg/m2 with a weight-related comorbidity)
Clinical diagnosis of T1D
Diabetes duration diagnosed ≥ 12 months ago
HbA1c ≤10% at screening and within the past 90 days
Stable reported insulin dosing in the past 90 days (within 15%)

Key exclusion criteria

Use of adjunctive diabetes therapies or anti-obesity medications (including any GLP-1 agonist) currently or within the past 6 months.
Insulin dosing \<0.5 units/kg/day
Current psychiatric conditions impacting weight, including known eating disorders
Contraindications to study medications, including:
Personal history of pancreatitis, renal impairment, or known liver disease other than non-alcoholic hepatic steatosis

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Connecticut1 site

Yale Pediatric Diabetes Center, Adult and Children's Progam
New Haven, Connecticut

Follow this trial

We email you if NCT06411210 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: July 16, 2024. Expected completion: June 30, 2028. Last updated on ClinicalTrials.gov: August 4, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.